US20100112595A1 - Bisulfite Conversion Reagent - Google Patents

Bisulfite Conversion Reagent Download PDF

Info

Publication number
US20100112595A1
US20100112595A1 US12/687,066 US68706610A US2010112595A1 US 20100112595 A1 US20100112595 A1 US 20100112595A1 US 68706610 A US68706610 A US 68706610A US 2010112595 A1 US2010112595 A1 US 2010112595A1
Authority
US
United States
Prior art keywords
packaged
ion
bisulfite
bisulfite solution
counter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/687,066
Inventor
Yafei Liu
Haley O. Fiske
Steven M. Menchen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Priority to US12/687,066 priority Critical patent/US20100112595A1/en
Publication of US20100112595A1 publication Critical patent/US20100112595A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D5/00—Sulfates or sulfites of sodium, potassium or alkali metals in general
    • C01D5/14—Preparation of sulfites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B17/00—Sulfur; Compounds thereof
    • C01B17/62—Methods of preparing sulfites in general
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F5/00—Compounds of magnesium
    • C01F5/42—Magnesium sulfites

Definitions

  • the present teachings relate generally to methods and materials for the specific conversion of cytosine to uracil.
  • methylation of DNA is useful in many research, diagnostic, medical, forensic, and industrial fields. Particularly, methylation of cytosine in genomic DNA has been correlated with lack of gene expression, and in some instances can be indicative of early and frequent alterations found in some cancers. Thus, the ability to assess the methylation status of DNA is significant.
  • the bisulfite reagent can comprise at least one counter-ion selected from a monovalent ion, a divalent ion and combinations thereof.
  • the counter-ion can be a monovalent ion.
  • the counter-ion can be a monovalent ion selected from sodium, lithium, potassium, ammonium, tetraalkylammonium and combinations thereof.
  • the counter-ion can be a divalent ion.
  • the counter-ion can be a divalent ion selected from magnesium, manganese, calcium and combinations thereof.
  • the bisulfite counter-ion can be ammonium.
  • the bisulfite counter-ion can be tetraalkylammonium.
  • the oxygen-impermeable container can be selected from an ampoule, a hermetically sealed bag, a capsule, etc.
  • the oxygen-impermeable container can be an ampoule.
  • the ampoule can be an amber glass ampoule.
  • the oxygen-impermeable container can be a capsule.
  • the capsule can comprise a substantially oxygen-impermeable thermal plastic polymer.
  • the present teachings provide for kits comprising packaged bisulfite solutions described herein.
  • the present teachings provide for a packaged bisulfite solution comprising an aqueous deoxygenated solution of a bisulfite reagent enclosed within an oxygen-impermeable container, wherein said solution contains less than 10 ppm dissolved oxygen and wherein after six months, the solution has a bisulfite concentration that is at least 90% of the original concentration.
  • the aqueous deoxygenated solution can be a solution containing bisulfite ion in a concentration of from about 0.5 molar (e.g.-0.5 M) to about 2.5 M. In further embodiments, the solution contains bisulfite ion in a concentration of from about 1 M to about 2 M.
  • the bisulfite is present at a concentration of at least about 1M.
  • the bisulfite solution can have a bisulfite concentration that is at least 90% of the original concentration. In some embodiments, after six months, the bisulfite solution can have a bisulfite concentration that is at least 95% of the original concentration. In some embodiments, after six months, the bisulfite solution can have a bisulfite concentration that is at least 99% of the original concentration.
  • Bisulfite concentration can be determined by, for example, spectroscopic determination using Ellman's reagent or iodine titration using a starch indicator according to the following reaction (see, for example, Sadegh, C., et al., MIT Undergraduate Research Journal, 8, 39-42 (2003) and references cited therein):
  • bisulfite ion has its accustomed meaning of HSO 3 ⁇ .
  • bisulfite is used as an aqueous solution of a bisulfite salt, for example magnesium bisulfite, which has the formula Mg(HSO 3 ) 2 , and sodium bisulfite, which has the formula NaHSO 3 .
  • Suitable counter-ions for the bisulfite compound may be monovalent or divalent.
  • monovalent cations include, without limitation, sodium, lithium, potassium, ammonium, and tetraalkylammonium.
  • divalent cations include, without limitation, magnesium, manganese, and calcium.
  • the bisulfite solution can further comprise a quaternary ammonium catalyst.
  • quaternary ammonium catalyst includes, without limitation, salts of quaternary ammonium compounds, including without limitation quaternary alkyl ammonium salts.
  • Examples of quaternary ammonium catalysts include, but are not limited to, quaternary alkyl ammonium halides, for example quaternary methyl ammonium bromide, quaternary ammonium chlorides, tetraethyl ammonium hydroxide, tetraethylammonium chloride, tetrabutyl ammonium chloride, tetrabutyl ammonium bromide, and the like.
  • quaternary ammonium catalysts include, but are not limited to, quaternary alkyl ammonium halides, for example quaternary methyl ammonium bromide, quaternary ammonium chlorides, tetraethyl ammonium hydrox
  • the quaternary amine catalyst comprises a quaternary ammonium compound, or a derivative thereof. In further embodiments, the quaternary amine catalyst comprises a quaternary alkyl ammonium salt. In yet further embodiments, the quaternary amine catalyst comprises a quaternary alkyl ammonium halide, for example a quaternary ammonium chloride or a quaternary ammonium bromide.
  • the quaternary amine catalyst comprises at least one of quaternary methyl ammonium bromide, tetraethyl ammonium hydroxide, tetraethylammonium chloride, tetrabutylammonium chloride and tetrabutylammonium bromide.
  • the bisulfite solution further comprises a polyamine catalyst.
  • polyamine is intended to refer to compounds having more than one amine group, and their salts.
  • polyamines include, without limitation, diamines, triamines such as diethylene triamine (DETA), guanidine and tetramethyl guanidine; tetraamines, such as spermine; compounds having the Formula I as disclosed herein, and other compounds containing two or more amine groups, and salts of the same.
  • triamine refers to compounds having three amino groups, including but not limited to diethylene triamine (DETA), guanidine HCl, tetramethyl guanidine, and the like.
  • Suitable oxygen-impermeable containers include, but are not limited to, ampoules, hermetically sealed bags, capsules, oxygen-impermeable vials, and the like.
  • the oxygen-impermeable container can be an oxygen impermeable vial.
  • Suitable oxygen-impermeable vials include, but are not limited to, glass or plastic screw-top vials having a sealing film adhered to the upper edge of the vial opening.
  • Suitable sealing films include, but are not limited to, oxygen-impermeable thermal plastic polymer, such as Barex® films.
  • the oxygen-impermeable container can be an ampoule. In some embodiments, the oxygen-impermeable container can be an amber glass ampoule. In some embodiments, the oxygen-impermeable container can be a plastic ampoule. Suitable ampoules and methods of filling ampoules are well known in the art. As used herein “ampoule” refers to any glass or plastic vial that is hermetically sealed and broken-off at one end to release the contents held therein. Plastic ampoules can also include, but are not limited to, those described in U.S. Pat. Nos. 6,379,069 and 6,641,319. In some embodiments, the oxygen-impermeable container can be a capsule.
  • the oxygen-impermeable container can be a vial or an Eppendorf tube that is hermetically sealed inside a bag or other oxygen-impermeable flexible package.
  • Oxygen-impermeable packages can include those comprising a Barex® film.
  • the solution contains less than 10 ppm dissolved oxygen. In some embodiments the solution contains less than 5 ppm dissolved oxygen. In some embodiments the solution contains less than 1 ppm dissolved oxygen.
  • the amount of dissolved oxygen can be determined by, for example, commercially available meters, such as the DO 4000 dissolved oxygen meter (Lamotte Co., Chestertown, Md.).
  • a packaged bisulfite solution of the present teachings by dispensing water into a container of the type described above, degassing the water by bubbling a non-reactive gas through the water for 10 minutes, adding reagents to form a bisulfite solution useful in DNA methylation analysis, degassing the solution a second time, and sealing the container.
  • Suitable non-reactive gases include, but are not limited to, nitrogen (N 2 ), helium (He) and argon (Ar).
  • Suitable reagents include those described above.
  • kits for carrying out sodium bisulfite conversion of cytosine to uracil comprises kits for carrying out sodium bisulfite conversion of cytosine to uracil.
  • a kit of the invention comprises a packaged bisulfite solution according to the present teachings, and optionally includes other pre-measured ingredients required for carrying out the bisulfite reaction.
  • the present teachings provide for a kit containing pre-packaged materials sufficient to prepare multiple samples.
  • the materials will be pre-packaged in suitable containers, such as Eppendorf tubes or other vessels as described above, as appropriate.

Abstract

Disclosed, among other things, are packaged bisulfite solutions comprising bisulfite reagent in an oxygen-impermeable container and methods.

Description

  • This application is a Continuation of U.S. patent application Ser. No. 11/270,325 filed Nov. 8, 2005, which claims a priority benefit under 35 U.S.C. §119(e) from U.S. Application Ser. No. 60/626,228 filed Nov. 8, 2004, each of which is incorporated herein by reference in its entirety.
  • The present teachings relate generally to methods and materials for the specific conversion of cytosine to uracil.
  • Assessment of methylation of DNA is useful in many research, diagnostic, medical, forensic, and industrial fields. Particularly, methylation of cytosine in genomic DNA has been correlated with lack of gene expression, and in some instances can be indicative of early and frequent alterations found in some cancers. Thus, the ability to assess the methylation status of DNA is significant.
  • Assessment of DNA methylation generally involves the conversion of cytosine to uracil. One basic method for such conversion employs sodium bisulfite. Over the years, the method has been improved in attempts to overcome disadvantages that include tedious procedures, lengthy reaction times, and DNA degradation. One commonly used sodium bisulfite conversion protocol is taught by J. Herman, see Herman, J., Proc. Natl. Acad. Sci. 93, 9821-26 (1996), incorporated herein by reference in its entirety. Despite the attempts to improve the protocol, it is still required to prepare fresh solutions of sodium bisulfite (NaHSO3) that include a stabilizing reagent (antioxidant) such as hydroquinone. Generally, the protocol also involves long reaction times and tedious clean-up procedures.
  • Given the importance of assessment of DNA methylation, it can be seen that there is a need for improved reagents and methods for conversion of cytosine to uracil.
  • In some embodiments, the present teachings provide for a packaged bisulfite solution comprising an aqueous deoxygenated solution of a bisulfite reagent enclosed within an oxygen-impermeable container, wherein after six months, the solution has a bisulfite concentration that is at least 90% of the original concentration. In some embodiments, the solution contains less than 10 ppm dissolved oxygen.
  • In some embodiments, the bisulfite reagent can comprise at least one counter-ion selected from a monovalent ion, a divalent ion and combinations thereof. In some embodiments, the counter-ion can be a monovalent ion. In some embodiments, the counter-ion can be a monovalent ion selected from sodium, lithium, potassium, ammonium, tetraalkylammonium and combinations thereof. In some embodiments, the counter-ion can be a divalent ion. In some embodiments, the counter-ion can be a divalent ion selected from magnesium, manganese, calcium and combinations thereof. In some embodiments, the bisulfite counter-ion can be ammonium. In some embodiments, the bisulfite counter-ion can be tetraalkylammonium.
  • In some embodiments, the oxygen-impermeable container can be selected from an ampoule, a hermetically sealed bag, a capsule, etc. In some embodiments, the oxygen-impermeable container can be an ampoule. In some embodiments, the ampoule can be an amber glass ampoule. In some embodiments, the oxygen-impermeable container can be a capsule. In some embodiments, the capsule can comprise a substantially oxygen-impermeable thermal plastic polymer. In some embodiments, the present teachings provide for kits comprising packaged bisulfite solutions described herein.
  • It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “comprising”, as well as other forms, such as “comprises” and “comprised”, is not intended to be limiting.
  • In some embodiments, the present teachings provide for a packaged bisulfite solution comprising an aqueous deoxygenated solution of a bisulfite reagent enclosed within an oxygen-impermeable container, wherein said solution contains less than 10 ppm dissolved oxygen and wherein after six months, the solution has a bisulfite concentration that is at least 90% of the original concentration.
  • In some embodiments, the aqueous deoxygenated solution can be a solution containing bisulfite ion in a concentration of from about 0.5 molar (e.g.-0.5 M) to about 2.5 M. In further embodiments, the solution contains bisulfite ion in a concentration of from about 1 M to about 2 M.
  • In some embodiments, the bisulfite is present at a concentration of at least about 1M.
  • In some embodiments, after six months, the bisulfite solution can have a bisulfite concentration that is at least 90% of the original concentration. In some embodiments, after six months, the bisulfite solution can have a bisulfite concentration that is at least 95% of the original concentration. In some embodiments, after six months, the bisulfite solution can have a bisulfite concentration that is at least 99% of the original concentration. Bisulfite concentration can be determined by, for example, spectroscopic determination using Ellman's reagent or iodine titration using a starch indicator according to the following reaction (see, for example, Sadegh, C., et al., MIT Undergraduate Research Journal, 8, 39-42 (2003) and references cited therein):

  • SO3 2−+I3 −+H2O→SO4 2−+2 H+3 I−
  • As used herein, bisulfite ion has its accustomed meaning of HSO3 −. Typically, bisulfite is used as an aqueous solution of a bisulfite salt, for example magnesium bisulfite, which has the formula Mg(HSO3)2, and sodium bisulfite, which has the formula NaHSO3.
  • Suitable counter-ions for the bisulfite compound may be monovalent or divalent. Examples of monovalent cations include, without limitation, sodium, lithium, potassium, ammonium, and tetraalkylammonium. Suitable divalent cations include, without limitation, magnesium, manganese, and calcium.
  • In some embodiments, the bisulfite solution can further comprise a quaternary ammonium catalyst. The term “quaternary ammonium catalyst” includes, without limitation, salts of quaternary ammonium compounds, including without limitation quaternary alkyl ammonium salts. Examples of quaternary ammonium catalysts include, but are not limited to, quaternary alkyl ammonium halides, for example quaternary methyl ammonium bromide, quaternary ammonium chlorides, tetraethyl ammonium hydroxide, tetraethylammonium chloride, tetrabutyl ammonium chloride, tetrabutyl ammonium bromide, and the like. A more detailed discussion of uses of quaternary ammonium catalysts is provided in U.S. Provisional Patent Application Nos. 60/499,106 and 60/523,054, each of which is incorporated herein by reference in its entirety for all it discloses.
  • In some embodiments of the invention, the quaternary amine catalyst comprises a quaternary ammonium compound, or a derivative thereof. In further embodiments, the quaternary amine catalyst comprises a quaternary alkyl ammonium salt. In yet further embodiments, the quaternary amine catalyst comprises a quaternary alkyl ammonium halide, for example a quaternary ammonium chloride or a quaternary ammonium bromide. In some embodiments, the quaternary amine catalyst comprises at least one of quaternary methyl ammonium bromide, tetraethyl ammonium hydroxide, tetraethylammonium chloride, tetrabutylammonium chloride and tetrabutylammonium bromide.
  • In some embodiments, the bisulfite solution further comprises a polyamine catalyst. As used herein, the term “polyamine” is intended to refer to compounds having more than one amine group, and their salts. Thus, “polyamines” include, without limitation, diamines, triamines such as diethylene triamine (DETA), guanidine and tetramethyl guanidine; tetraamines, such as spermine; compounds having the Formula I as disclosed herein, and other compounds containing two or more amine groups, and salts of the same. As used herein, the term “triamine” refers to compounds having three amino groups, including but not limited to diethylene triamine (DETA), guanidine HCl, tetramethyl guanidine, and the like. A more thorough discussion of uses of polyamine catalysts is provided in U.S. Provisional Patent Application Nos. 60/520,942 and 60/499,113, each of which is incorporated herein by reference in its entirety for all it discloses.
  • Suitable oxygen-impermeable containers include, but are not limited to, ampoules, hermetically sealed bags, capsules, oxygen-impermeable vials, and the like. In some embodiments, the oxygen-impermeable container can be an oxygen impermeable vial. Suitable oxygen-impermeable vials include, but are not limited to, glass or plastic screw-top vials having a sealing film adhered to the upper edge of the vial opening. Suitable sealing films include, but are not limited to, oxygen-impermeable thermal plastic polymer, such as Barex® films.
  • In some embodiments, the oxygen-impermeable container can be an ampoule. In some embodiments, the oxygen-impermeable container can be an amber glass ampoule. In some embodiments, the oxygen-impermeable container can be a plastic ampoule. Suitable ampoules and methods of filling ampoules are well known in the art. As used herein “ampoule” refers to any glass or plastic vial that is hermetically sealed and broken-off at one end to release the contents held therein. Plastic ampoules can also include, but are not limited to, those described in U.S. Pat. Nos. 6,379,069 and 6,641,319. In some embodiments, the oxygen-impermeable container can be a capsule. In some embodiments, the oxygen-impermeable container can be a vial or an Eppendorf tube that is hermetically sealed inside a bag or other oxygen-impermeable flexible package. Oxygen-impermeable packages can include those comprising a Barex® film.
  • In some embodiments the solution contains less than 10 ppm dissolved oxygen. In some embodiments the solution contains less than 5 ppm dissolved oxygen. In some embodiments the solution contains less than 1 ppm dissolved oxygen. The amount of dissolved oxygen can be determined by, for example, commercially available meters, such as the DO 4000 dissolved oxygen meter (Lamotte Co., Chestertown, Md.).
  • One of skill in the art could prepare a packaged bisulfite solution of the present teachings by dispensing water into a container of the type described above, degassing the water by bubbling a non-reactive gas through the water for 10 minutes, adding reagents to form a bisulfite solution useful in DNA methylation analysis, degassing the solution a second time, and sealing the container. Suitable non-reactive gases include, but are not limited to, nitrogen (N2), helium (He) and argon (Ar). Suitable reagents include those described above.
  • In some embodiments, the invention provides for kits for carrying out sodium bisulfite conversion of cytosine to uracil. In one embodiment, a kit of the invention comprises a packaged bisulfite solution according to the present teachings, and optionally includes other pre-measured ingredients required for carrying out the bisulfite reaction. In some embodiments, the present teachings provide for a kit containing pre-packaged materials sufficient to prepare multiple samples. In some embodiments, the materials will be pre-packaged in suitable containers, such as Eppendorf tubes or other vessels as described above, as appropriate.
  • All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.
  • The various embodiments described herein are merely illustrative embodiments meant to describe the invention. Applicant does not limit the invention to these embodiments. Rather, applicant acknowledges that those reasonably skilled in the art will readily recognize additional variants that do not differ from the scope and spirit of the invention.

Claims (20)

1) A packaged bisulfite solution comprising an aqueous deoxygenated solution of a bisulfite reagent enclosed within an oxygen-impermeable container, wherein after six months, the solution has a bisulfite concentration that is at least 90% of the original concentration.
2) The packaged bisulfite solution of claim 1, wherein the bisulfite reagent comprises at least one counter-ion selected from a monovalent ion, a divalent ion and combinations thereof.
3) The packaged bisulfite solution of claim 2, wherein the counter-ion is a monovalent ion.
4) The packaged bisulfite solution of claim 2, wherein the counter-ion is a monovalent ion selected from sodium, lithium, potassium, ammonium, tetraalkylammonium and combinations thereof.
5) The packaged bisulfite solution of claim 4, wherein the counter-ion is sodium.
6) The packaged bisulfite solution of claim 4, wherein the counter-ion is lithium or potassium.
7) The packaged bisulfite solution of claim 4, wherein the counter-ion is ammonium.
8) The packaged bisulfite solution of claim 4, wherein the counter-ion is tetraalkylammonium.
9) The packaged bisulfite of claim 2, wherein the counter-ion is a divalent ion.
10) The packaged bisulfite solution of claim 2, wherein the counter-ion is a divalent ion selected from magnesium, manganese, calcium and combinations thereof.
11) The packaged bisulfite solution of claim 10, wherein the counter-ion is magnesium.
12) The packaged bisulfite solution of claim 10, wherein the counter-ion is manganese.
13) The packaged bisulfite solution of claim 10, wherein the counter-ion is calcium.
14) The packaged bisulfite solution according to any one of the preceding claims, wherein the oxygen-impermeable container is selected from an ampoule, a hermetically sealed bag, a capsule, etc.
15) The packaged bisulfite solution of claim 14, wherein the oxygen-impermeable container is an ampoule.
16) The packaged bisulfite solution of claim 15, wherein the ampoule is an amber glass ampoule.
17) The packaged bisulfite solution of claim 15, wherein the oxygen-impermeable container is a capsule.
18) The packaged bisulfite solution of claim 17, wherein the capsule comprises a substantially oxygen-impermeable thermal plastic polymer.
19) The packaged bisulfite solution according to any one of the preceding claims, wherein the bisulfite solution contains less than 10 ppm dissolved oxygen.
20) A kit comprising the packaged bisulfite solution according to claim 1.
US12/687,066 2004-11-08 2010-01-13 Bisulfite Conversion Reagent Abandoned US20100112595A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/687,066 US20100112595A1 (en) 2004-11-08 2010-01-13 Bisulfite Conversion Reagent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62622804P 2004-11-08 2004-11-08
US11/270,325 US7658288B2 (en) 2004-11-08 2005-11-08 Bisulfite conversion reagent
US12/687,066 US20100112595A1 (en) 2004-11-08 2010-01-13 Bisulfite Conversion Reagent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/270,325 Continuation US7658288B2 (en) 2004-11-08 2005-11-08 Bisulfite conversion reagent

Publications (1)

Publication Number Publication Date
US20100112595A1 true US20100112595A1 (en) 2010-05-06

Family

ID=36641427

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/270,325 Expired - Fee Related US7658288B2 (en) 2004-11-08 2005-11-08 Bisulfite conversion reagent
US12/687,066 Abandoned US20100112595A1 (en) 2004-11-08 2010-01-13 Bisulfite Conversion Reagent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/270,325 Expired - Fee Related US7658288B2 (en) 2004-11-08 2005-11-08 Bisulfite conversion reagent

Country Status (1)

Country Link
US (2) US7658288B2 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10160987B2 (en) 2016-04-07 2018-12-25 Rebecca F. McClure Composition and method for processing DNA
US10512270B2 (en) 2016-04-01 2019-12-24 Eagle Us 2 Llc Acid tablet composition and methods of preparing and using the same
WO2021116107A1 (en) 2019-12-13 2021-06-17 Evonik Operations Gmbh A chicken methylation clock
WO2022023208A1 (en) 2020-07-30 2022-02-03 Evonik Operations Gmbh Dna-methylation-based quality control of the origin of organisms
WO2022117382A1 (en) 2020-12-04 2022-06-09 Evonik Operations Gmbh A method for classifying the gut inflammation status in avian species
WO2023031378A1 (en) 2021-09-06 2023-03-09 Evonik Operations Gmbh Dna-methylation-based certification of quality
WO2023148198A1 (en) 2022-02-07 2023-08-10 Evonik Operations Gmbh An epigentic clock for the galliformes family
WO2023213573A1 (en) 2022-05-03 2023-11-09 Evonik Operations Gmbh Diagnostic biomarker for oxidative stress
WO2023213576A1 (en) 2022-05-03 2023-11-09 Evonik Operations Gmbh Detecting oxidative stress in cell(s) using epigenetic means
WO2023213574A1 (en) 2022-05-03 2023-11-09 Evonik Operations Gmbh Epigenetic markers for detecting oxidative stress
WO2024008735A1 (en) 2022-07-08 2024-01-11 Evonik Operations Gmbh Detecting antibiotic and/or chemical use in animals using epigenetic means
WO2024008736A1 (en) 2022-07-08 2024-01-11 Evonik Operations Gmbh Detecting antibiotic and/or chemical use in aquatic animals using epigenetic means
WO2024012958A1 (en) 2022-07-12 2024-01-18 Evonik Operations Gmbh Certification of animal-derived product(s) based on dna-methylation
WO2024046839A1 (en) 2022-09-01 2024-03-07 Evonik Operations Gmbh Dna-methylation detection in animal-derived products
WO2024046840A1 (en) 2022-09-01 2024-03-07 Evonik Operations Gmbh Method of assessing protein production in cho cells
WO2024046841A1 (en) 2022-09-01 2024-03-07 Evonik Operations Gmbh Identifying breeding conditions of livestock using epigenetics
WO2024046838A1 (en) 2022-09-01 2024-03-07 Evonik Operations Gmbh Multi-species chip to detect dna-methylation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486634B2 (en) * 2007-11-06 2013-07-16 Ambergen, Inc. Amplifying bisulfite-treated template

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888969A (en) * 1972-09-05 1975-06-10 Mitsubishi Chem Ind Antioxidant for the aqueous solutions of sulfite and/or bisulfite of sodium or potassium and process for preventing the oxidation of said aqueous solution
US3971734A (en) * 1973-08-28 1976-07-27 Nl Industries, Inc. Sulfite compositions, aqueous sulfite solutions and method of decreasing their rate of oxidation
US4231894A (en) * 1980-01-17 1980-11-04 Betz Laboratories, Inc. Stabilized alkali metal bisulfite or sulfite-catalyzed solutions
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
US5683588A (en) * 1995-09-21 1997-11-04 Betzdearborn Inc. Stabilization of catalyzed aqueous sulfite and bisulfite ion solutions
US6214556B1 (en) * 1997-11-27 2001-04-10 Epigenomics Ag Method for producing complex DNA methylation fingerprints
US6251594B1 (en) * 1997-06-09 2001-06-26 Usc/Norris Comprehensive Cancer Ctr. Cancer diagnostic method based upon DNA methylation differences
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6451289B2 (en) * 2000-03-24 2002-09-17 Sepracor Inc. Albuterol formulations
US6511810B2 (en) * 2000-07-03 2003-01-28 Applera Corporation Polynucleotide sequence assay
US20030191070A1 (en) * 2000-06-06 2003-10-09 Kinuko Oku Medical composition kit for treating lesioned abnormal tissue
US20030218542A1 (en) * 2000-12-01 2003-11-27 Leif Barendt Camera supervised motion safety system
US20040121359A1 (en) * 2001-01-29 2004-06-24 Kurt Berlin Fluorescence polarisation
US20040152080A1 (en) * 2000-06-19 2004-08-05 Kurt Berlin Method for detecting cytosine methylations
US20050089898A1 (en) * 2003-08-29 2005-04-28 Applera Corporation Method and materials for quaternary amine catalyzed bisulfite conversion of cytosine to uracil
US20050095623A1 (en) * 2003-08-29 2005-05-05 Applera Corporation Method and materials for bisulfite conversion of cytosine to uracil
US20060138399A1 (en) * 2002-08-22 2006-06-29 Mitsushi Itano Removing solution
US7368239B2 (en) * 2003-08-29 2008-05-06 Applera Corporation Method and materials for polyamine catalyzed bisulfite conversion of cytosine to uracil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07265082A (en) 1994-03-28 1995-10-17 Makoto Komiyama Method for chemically converting nucleic acid
DE10050942B4 (en) 2000-10-10 2005-11-17 Epigenomics Ag Method for the detection of cytosine methylations
AU2002213125B2 (en) 2000-10-11 2007-11-22 Applied Biosystems, Llc. Fluorescent nucleobase conjugates having anionic linkers
DE10151055B4 (en) 2001-10-05 2005-05-25 Epigenomics Ag Method for detecting cytosine methylation in CpG islands
EP1470254A2 (en) 2002-01-30 2004-10-27 Epigenomics AG Method for the analysis of cytosine methylation patterns
AU2003236461B2 (en) 2002-08-29 2009-05-28 Epigenomics Ag Improved method for bisulfite treatment
JP2006516391A (en) 2003-01-29 2006-07-06 エフ．ホフマン−ラ　ロシュ　アーゲー Improved method of bisulfite treatment.

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888969A (en) * 1972-09-05 1975-06-10 Mitsubishi Chem Ind Antioxidant for the aqueous solutions of sulfite and/or bisulfite of sodium or potassium and process for preventing the oxidation of said aqueous solution
US3971734A (en) * 1973-08-28 1976-07-27 Nl Industries, Inc. Sulfite compositions, aqueous sulfite solutions and method of decreasing their rate of oxidation
US4231894A (en) * 1980-01-17 1980-11-04 Betz Laboratories, Inc. Stabilized alkali metal bisulfite or sulfite-catalyzed solutions
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
US5683588A (en) * 1995-09-21 1997-11-04 Betzdearborn Inc. Stabilization of catalyzed aqueous sulfite and bisulfite ion solutions
US6251594B1 (en) * 1997-06-09 2001-06-26 Usc/Norris Comprehensive Cancer Ctr. Cancer diagnostic method based upon DNA methylation differences
US6214556B1 (en) * 1997-11-27 2001-04-10 Epigenomics Ag Method for producing complex DNA methylation fingerprints
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6451289B2 (en) * 2000-03-24 2002-09-17 Sepracor Inc. Albuterol formulations
US20030191070A1 (en) * 2000-06-06 2003-10-09 Kinuko Oku Medical composition kit for treating lesioned abnormal tissue
US7381419B2 (en) * 2000-06-06 2008-06-03 Lequio Pharma Co., Ltd. Medical composition kit for treating lesioned abnormal tissue
US20040152080A1 (en) * 2000-06-19 2004-08-05 Kurt Berlin Method for detecting cytosine methylations
US6511810B2 (en) * 2000-07-03 2003-01-28 Applera Corporation Polynucleotide sequence assay
US20030218542A1 (en) * 2000-12-01 2003-11-27 Leif Barendt Camera supervised motion safety system
US20040121359A1 (en) * 2001-01-29 2004-06-24 Kurt Berlin Fluorescence polarisation
US20060138399A1 (en) * 2002-08-22 2006-06-29 Mitsushi Itano Removing solution
US20050089898A1 (en) * 2003-08-29 2005-04-28 Applera Corporation Method and materials for quaternary amine catalyzed bisulfite conversion of cytosine to uracil
US20050095623A1 (en) * 2003-08-29 2005-05-05 Applera Corporation Method and materials for bisulfite conversion of cytosine to uracil
US7368239B2 (en) * 2003-08-29 2008-05-06 Applera Corporation Method and materials for polyamine catalyzed bisulfite conversion of cytosine to uracil
US7534873B2 (en) * 2003-08-29 2009-05-19 Applied Biosystems, Llc Method and materials for quaternary amine catalyzed bisulfite conversion of cytosine to uracil

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512270B2 (en) 2016-04-01 2019-12-24 Eagle Us 2 Llc Acid tablet composition and methods of preparing and using the same
US11058118B2 (en) 2016-04-01 2021-07-13 Eagle Us 2 Llc Acid tablet composition and methods of preparing and using the same
US10160987B2 (en) 2016-04-07 2018-12-25 Rebecca F. McClure Composition and method for processing DNA
WO2021116107A1 (en) 2019-12-13 2021-06-17 Evonik Operations Gmbh A chicken methylation clock
WO2022023208A1 (en) 2020-07-30 2022-02-03 Evonik Operations Gmbh Dna-methylation-based quality control of the origin of organisms
WO2022117382A1 (en) 2020-12-04 2022-06-09 Evonik Operations Gmbh A method for classifying the gut inflammation status in avian species
WO2023031378A1 (en) 2021-09-06 2023-03-09 Evonik Operations Gmbh Dna-methylation-based certification of quality
WO2023148198A1 (en) 2022-02-07 2023-08-10 Evonik Operations Gmbh An epigentic clock for the galliformes family
WO2023213573A1 (en) 2022-05-03 2023-11-09 Evonik Operations Gmbh Diagnostic biomarker for oxidative stress
WO2023213576A1 (en) 2022-05-03 2023-11-09 Evonik Operations Gmbh Detecting oxidative stress in cell(s) using epigenetic means
WO2023213574A1 (en) 2022-05-03 2023-11-09 Evonik Operations Gmbh Epigenetic markers for detecting oxidative stress
WO2024008735A1 (en) 2022-07-08 2024-01-11 Evonik Operations Gmbh Detecting antibiotic and/or chemical use in animals using epigenetic means
WO2024008736A1 (en) 2022-07-08 2024-01-11 Evonik Operations Gmbh Detecting antibiotic and/or chemical use in aquatic animals using epigenetic means
WO2024012958A1 (en) 2022-07-12 2024-01-18 Evonik Operations Gmbh Certification of animal-derived product(s) based on dna-methylation
WO2024046839A1 (en) 2022-09-01 2024-03-07 Evonik Operations Gmbh Dna-methylation detection in animal-derived products
WO2024046840A1 (en) 2022-09-01 2024-03-07 Evonik Operations Gmbh Method of assessing protein production in cho cells
WO2024046841A1 (en) 2022-09-01 2024-03-07 Evonik Operations Gmbh Identifying breeding conditions of livestock using epigenetics
WO2024046838A1 (en) 2022-09-01 2024-03-07 Evonik Operations Gmbh Multi-species chip to detect dna-methylation

Also Published As

Publication number Publication date
US20060148853A1 (en) 2006-07-06
US7658288B2 (en) 2010-02-09

Similar Documents

Publication Publication Date Title
US7658288B2 (en) Bisulfite conversion reagent
AU619318B2 (en) Water soluble organic ammonium perhalides
CN1095670C (en) A package from for bicarbonate-containing powdery pharmaceutical compositions and a method of stabilizing the compositions
Felsenfeld et al. The interaction of polynucleotides with metal ions, amino acids, and polyamines
US20190062545A1 (en) Transparent and antistatic pmma composition
TW201006497A (en) Liquid composition comprising cisplatin-coordinating compound
WO2001056575A1 (en) Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid
BR0011442A (en) Process for the preparation of ethylene homo- and copolymers by intense mixing of a reactive reaction component with a current flow medium
US10138266B2 (en) Method of cutting out RNA oligonucleotide
US9018418B2 (en) Method for preparation of aryl poly(oxalkyl) quaternary ammonium compound
CN101494986A (en) Solid biocidal compositions and methods of using the same
ATE282565T1 (en) WATER SOLUBLE PACKAGING AND ASSOCIATED LIQUID CONTENTS
RU2008119498A (en) CARRIER COMPOSITION FOR NUCLEIC ACID TRANSPORT
EP2102075A1 (en) Storage of ampoules containing pharmaceutical formulations using a sealed container comprising an oxygen scavenger
AU2005216846A1 (en) A medical solution, a method for producing said medical solution and use thereof
CN108404809A (en) A kind of application of star-like carboxylic acid group's zwitterionic surfactant as dispersant
BR112014020032B1 (en) metallic amides complexed with alkaline earth metals, their use and their preparation process
JP3914029B2 (en) Stabilized vinylpyrrolidone polymer composition
Macartney et al. Kinetics of formation of (thiourea) pentacyanoferrate (II) complexes in aqueous perchlorate media
FI81718B (en) ADSTRINGERANDE TANDPASTA.
JPH11157805A (en) Production kit for aqueous chlorine dioxide, aqueous chlorine dioxide precursor composition and production of aqueous chlorine dioxide
Sridhar et al. L-Citrullinium perchlorate
JPH05112387A (en) Sealed package of iodine and iodine containing compound
GB2365768A (en) Stable liquid composition containing pemetrexed
WO2021014957A1 (en) Bendamustine injection formulation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION